Sanjeev Deva

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 145 citations · Full text

Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial

Reuben Broom, Victoria Hinder, Katrina Sharples et al. · Clinical Genitourinary Cancer · 2014 · 40 citations

Zoledronic Acid, Urology, Surgical Oncology +7

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Ezra E.W. Cohen, Lisle M. Nabell, Deborah J. Wong et al. · Journal of Clinical Oncology · 2019 · 27 citations

Immunology, Immunoediting, Pathology +21

A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

Sanjeev Deva, J.-S. Lee, C.-C. Lin et al. · Annals of Oncology · 2018 · 16 citations · Full text

Immunology, Immunoediting, Phase Ia/ib Trial +17

Cardiac Troponin I and T in Checkpoint Inhibitor–associated Myositis and Myocarditis

Edmond Ang, Angela Mweempwa, Campbell Le Heron et al. · Journal of Immunotherapy · 2021 · 15 citations